Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Two days. That is how long it took Revolution Medicines to turn landmark Phase 3 pancreatic cancer data into the largest follow-on stock offering in
Beeline Medicines is a textbook example of how big pharma pipeline pruning creates biotech opportunity. Bristol Myers Squibb spent years developing these five immune disease
Revolution Medicines moved fast. Within hours of reporting the most significant pancreatic cancer data in years, the company launched a $750 million equity offering and
Pancreatic cancer is one of the most lethal and treatment-resistant malignancies in all of oncology. Five-year survival rates hover around 12%. In previously treated metastatic
The FDA issued a second complete response letter for Replimune’s RP1 in advanced melanoma on Friday, and the fallout is immediate. CEO Sushil Patel said
The most consequential week in biopharma this year ends with two developments that signal where the industry’s power structures are shifting. PhRMA CEO Steve Ubl
Sanofi’s post-Dupixent strategy came into sharper focus on Tuesday—and the picture is mixed. Lunsekimig, a bispecific Nanobody that simultaneously blocks TSLP and IL-13, met its
The M&A machine that defined Q1 has carried directly into Q2 without missing a beat. Gilead Sciences announced a definitive agreement to acquire Munich-based Tubulis
The biggest oral obesity event of the year happened last week, and it landed faster than anyone expected. The FDA approved Lilly’s Foundayo (orforglipron) on
This is the most consequential trade action to hit the pharmaceutical industry in modern history. President Trump signed a Section 232 proclamation on April 2
